SCHEDULE 13D/A: Gerald T. Proehl and Proehl Investment Ventures LLC Affirm 7.8% Stake in Dermata Therapeutics

Gerald T. Proehl and Proehl Investment Ventures LLC have filed Amendment No. 6 to their Schedule 13D, reaffirming their beneficial ownership of 7.8% of Dermata Therapeutics, Inc.'s common stock as of March 27, 2025.

Summary

• This document is Amendment No. 6 to the Schedule 13D filing for Dermata Therapeutics, Inc., updating beneficial ownership information.
• Gerald T. Proehl is reported to beneficially own an aggregate of 804,098 shares of Common Stock, which represents 7.8% of the Issuer's outstanding shares.
• Proehl Investment Ventures LLC (PIV) is reported to beneficially own an aggregate of 799,624 shares of Common Stock, also representing 7.8% of the Issuer's outstanding shares.
• Mr. Proehl's beneficial ownership includes 247 shares of Common Stock and stock options for 2,777 shares held directly, 799,508 shares and warrants for 116 shares held by PIV, and 855 shares and warrants for 595 shares held by certain trusts for which he is trustee.
• PIV's beneficial ownership includes 799,508 shares of Common Stock and warrants to purchase up to 116 shares of Common Stock held directly by PIV.
• The beneficial ownership percentages are calculated based on 10,265,118 shares of Common Stock outstanding as of March 27, 2025.
• No purchases or sales of Common Stock, or securities convertible into or exchangeable for Common Stock, were made by the Reporting Persons within the sixty days prior to March 27, 2025.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13D Amendment) that updates beneficial ownership information without indicating any significant positive or negative developments for the company or its operations. The ownership percentages remain consistent with previous filings, suggesting a neutral impact.

Future Outlook

NA

Industry Context

This Schedule 13D amendment is a routine regulatory filing detailing beneficial ownership and does not provide specific insights into broader industry trends or competitive landscape within the biotechnology or pharmaceutical sector where Dermata Therapeutics operates.

Stakeholder Impact

• This filing primarily impacts shareholders by providing transparency on significant beneficial ownership stakes, confirming the continued substantial holdings of Gerald T. Proehl and Proehl Investment Ventures LLC.

Key Dates

Keywords

Dermata Therapeutics, Gerald T. Proehl, Proehl Investment Ventures LLC, Schedule 13D, Beneficial Ownership, Common Stock, SEC Filing, Ownership Stake, Biotechnology, Pharmaceuticals